Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06934447 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE

StatusRecruiting
PhasePhase 1
Started2025-04-25
View on ClinicalTrials.gov ↗

Amendment history

2025-04-22
minor
Study Status, Study Description, Outcome Measures, References v1
Start date2025-04-08→2025-04-25
Secondary endpoints3 to 4 entries
Duration of disease response (DOR)
Study description+56 characters
Systemic lupus erythematosus (SLE) is a serioussevere autoimmune disease that can lead to extensive damage in multiple organs and systems, ultimatelypotentially resultingleading into disability and even deathmortality. Children afflicted with SLE are particularly atvulnerable risk ofto organ damage, especiallynotably toaffecting the kidneys, and tend to have a more severe and protracted [...] wever, due to the absence of a curative treatment, patients oftentypically requireneed lifelongto remain on medication indefinitely. In recent years, biological agents such as belimumab and r [...] ab have been introd [...]
Publicationsdetails revised at 7 of 7 entries
2025-04-11
minor
Original filing
This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-BCMA/CD70 CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Trial Details
NCT Number NCT06934447
Lead Sponsor The Children's Hospital of Zhejiang University School of Medicine
Collaborators: Chongqing Precision Biotech Co., Ltd
Conditions CAR T Cell Therapy, Systemic Lupus Erythematosus, BCMA
Enrollment 18 participants
Start Date 2025-04-25
Primary Completion 2028-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-25